Nymox Pharmaceutical is a clinical-stage biopharmaceutical company built entirely around a single drug candidate, NX-1207 (fexapotide triflutate), an intra-prostatic injection being developed for benign prostatic hyperplasia (BPH), an enlarged prostate condition causing urinary problems in men. Nymox is also exploring NX-1207 as a treatment for low-grade localized prostate cancer. Nymox has no approved products, no revenue, and no commercial infrastructure. The company's regulatory path has been troubled: Phase 3 U.S. trials failed their primary endpoints in 2014, and a 2022 FDA New Drug Application was refused before formal review. A Danish marketing application lapsed in 2024 and requires re-submission; a UK application is currently under review. If NX-1207 were ever approved, Nymox would likely commercialize it through licensing or partnerships with larger pharma companies, since Nymox has no sales force. The company funds operations entirely through equity issuances and has raised over $202M in equity since inception, accumulating over $212M in losses. Annual cash burn is around $2.6M, and as of year-end 2024, Nymox held only ~$75K in cash with negative working capital of ~$6.8M. Nymox's auditors have flagged substantial going concern doubt, and the company's survival depends on its ability to continue raising equity capital.